Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29980988 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2HRH3CHRNB2 | |
| SCHEMBL30471028 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2HRH3CHRNB2 | |
| SCHEMBL30551216 | 0.94 | CHRNB2 (0.47) | KDM4EALDH1A1SMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL24364211 | 0.94 | CHRNB2 (0.47) | KDM4EALDH1A1SMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL30551424 | 0.94 | CHRNB2 (0.47) | KDM4EALDH1A1SMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL29346681 | 0.94 | CHRNB2 (0.47) | KDM4EALDH1A1SMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL24233755 | 0.81 | SIGMAR1 (0.37) | — | |
| SCHEMBL24364939 | 0.81 | SIGMAR1 (0.37) | — | |
| SCHEMBL30469656 | 0.81 | SIGMAR1 (0.37) | — | |
| SCHEMBL25320597 | 0.80 | USP2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | KDM4E 3895/4885ALDH1A1 128/4885SMN1; SMN2 1943/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | KDM4E 3895/4885ALDH1A1 128/4885SMN1; SMN2 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.